Browse ID1

Summary
SymbolID1
Nameinhibitor of DNA binding 1, dominant negative helix-loop-helix protein
Aliases dJ857M17.1.2; bHLHb24; DNA-binding protein inhibitor ID-1; ID; class B basic helix-loop-helix protein 24; dJ ......
Chromosomal Location20q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Nucleus.
Domain PF00010 Helix-loop-helix DNA-binding domain
Function

Transcriptional regulator (lacking a basic DNA binding domain) which negatively regulates the basic helix-loop-helix (bHLH) transcription factors by forming heterodimers and inhibiting their DNA binding and transcriptional activity. Implicated in regulating a variety of cellular processes, including cellular growth, senescence, differentiation, apoptosis, angiogenesis, and neoplastic transformation. Inhibits skeletal muscle and cardiac myocyte differentiation. Regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-ARNTL/BMAL1 heterodimer (By similarity).

> Gene Ontology
 
Biological Process GO:0001503 ossification
GO:0001525 angiogenesis
GO:0001649 osteoblast differentiation
GO:0001667 ameboidal-type cell migration
GO:0001885 endothelial cell development
GO:0001886 endothelial cell morphogenesis
GO:0002064 epithelial cell development
GO:0003158 endothelium development
GO:0003382 epithelial cell morphogenesis
GO:0007015 actin filament organization
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0007179 transforming growth factor beta receptor signaling pathway
GO:0007507 heart development
GO:0007623 circadian rhythm
GO:0010621 negative regulation of transcription by transcription factor localization
GO:0010631 epithelial cell migration
GO:0010721 negative regulation of cell development
GO:0010769 regulation of cell morphogenesis involved in differentiation
GO:0010771 negative regulation of cell morphogenesis involved in differentiation
GO:0010975 regulation of neuron projection development
GO:0010977 negative regulation of neuron projection development
GO:0016358 dendrite development
GO:0022604 regulation of cell morphogenesis
GO:0030278 regulation of ossification
GO:0030279 negative regulation of ossification
GO:0030323 respiratory tube development
GO:0030324 lung development
GO:0030509 BMP signaling pathway
GO:0030856 regulation of epithelial cell differentiation
GO:0030857 negative regulation of epithelial cell differentiation
GO:0031345 negative regulation of cell projection organization
GO:0031589 cell-substrate adhesion
GO:0031647 regulation of protein stability
GO:0031648 protein destabilization
GO:0032091 negative regulation of protein binding
GO:0032231 regulation of actin filament bundle assembly
GO:0032233 positive regulation of actin filament bundle assembly
GO:0032956 regulation of actin cytoskeleton organization
GO:0032963 collagen metabolic process
GO:0032970 regulation of actin filament-based process
GO:0036164 cell-abiotic substrate adhesion
GO:0043392 negative regulation of DNA binding
GO:0043393 regulation of protein binding
GO:0043433 negative regulation of sequence-specific DNA binding transcription factor activity
GO:0043496 regulation of protein homodimerization activity
GO:0043534 blood vessel endothelial cell migration
GO:0043542 endothelial cell migration
GO:0044089 positive regulation of cellular component biogenesis
GO:0044236 multicellular organism metabolic process
GO:0044259 multicellular organismal macromolecule metabolic process
GO:0045446 endothelial cell differentiation
GO:0045601 regulation of endothelial cell differentiation
GO:0045602 negative regulation of endothelial cell differentiation
GO:0045665 negative regulation of neuron differentiation
GO:0045667 regulation of osteoblast differentiation
GO:0045668 negative regulation of osteoblast differentiation
GO:0045765 regulation of angiogenesis
GO:0046677 response to antibiotic
GO:0048511 rhythmic process
GO:0048514 blood vessel morphogenesis
GO:0048667 cell morphogenesis involved in neuron differentiation
GO:0048813 dendrite morphogenesis
GO:0048814 regulation of dendrite morphogenesis
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0050679 positive regulation of epithelial cell proliferation
GO:0050768 negative regulation of neurogenesis
GO:0050773 regulation of dendrite development
GO:0050774 negative regulation of dendrite morphogenesis
GO:0051017 actin filament bundle assembly
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051098 regulation of binding
GO:0051100 negative regulation of binding
GO:0051101 regulation of DNA binding
GO:0051493 regulation of cytoskeleton organization
GO:0051495 positive regulation of cytoskeleton organization
GO:0051961 negative regulation of nervous system development
GO:0060425 lung morphogenesis
GO:0060426 lung vasculature development
GO:0060541 respiratory system development
GO:0061572 actin filament bundle organization
GO:0070849 response to epidermal growth factor
GO:0071364 cellular response to epidermal growth factor stimulus
GO:0071407 cellular response to organic cyclic compound
GO:0071417 cellular response to organonitrogen compound
GO:0071559 response to transforming growth factor beta
GO:0071560 cellular response to transforming growth factor beta stimulus
GO:0071772 response to BMP
GO:0071773 cellular response to BMP stimulus
GO:0071867 response to monoamine
GO:0071868 cellular response to monoamine stimulus
GO:0071869 response to catecholamine
GO:0071870 cellular response to catecholamine stimulus
GO:0090074 negative regulation of protein homodimerization activity
GO:0090130 tissue migration
GO:0090132 epithelium migration
GO:1901342 regulation of vasculature development
GO:1901652 response to peptide
GO:1901653 cellular response to peptide
GO:1903025 regulation of RNA polymerase II regulatory region sequence-specific DNA binding
GO:1903026 negative regulation of RNA polymerase II regulatory region sequence-specific DNA binding
GO:1903350 response to dopamine
GO:1903351 cellular response to dopamine
GO:1990089 response to nerve growth factor
GO:1990090 cellular response to nerve growth factor stimulus
GO:2000171 negative regulation of dendrite development
GO:2000677 regulation of transcription regulatory region DNA binding
GO:2000678 negative regulation of transcription regulatory region DNA binding
Molecular Function GO:0008022 protein C-terminus binding
GO:0008134 transcription factor binding
GO:0043621 protein self-association
GO:0047485 protein N-terminus binding
GO:0070628 proteasome binding
Cellular Component GO:0005813 centrosome
> KEGG and Reactome Pathway
 
KEGG hsa04015 Rap1 signaling pathway
hsa04350 TGF-beta signaling pathway
hsa04390 Hippo signaling pathway
hsa04550 Signaling pathways regulating pluripotency of stem cells
Reactome R-HSA-2559583: Cellular Senescence
R-HSA-2262752: Cellular responses to stress
R-HSA-2559585: Oncogene Induced Senescence
Summary
SymbolID1
Nameinhibitor of DNA binding 1, dominant negative helix-loop-helix protein
Aliases dJ857M17.1.2; bHLHb24; DNA-binding protein inhibitor ID-1; ID; class B basic helix-loop-helix protein 24; dJ ......
Chromosomal Location20q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ID1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between ID1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
25924227MelanomaInhibit immunity (T cell function)Here we demonstrate that upregulation of the Inhibitor of Differentiation 1 (Id1), in response to tumour-derived factors, such as TGFβ, is responsible for the switch from dendritic cell (DC) differentiation to myeloid-derived suppressor cell expansion during tumour progression.
Summary
SymbolID1
Nameinhibitor of DNA binding 1, dominant negative helix-loop-helix protein
Aliases dJ857M17.1.2; bHLHb24; DNA-binding protein inhibitor ID-1; ID; class B basic helix-loop-helix protein 24; dJ ......
Chromosomal Location20q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ID1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolID1
Nameinhibitor of DNA binding 1, dominant negative helix-loop-helix protein
Aliases dJ857M17.1.2; bHLHb24; DNA-binding protein inhibitor ID-1; ID; class B basic helix-loop-helix protein 24; dJ ......
Chromosomal Location20q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ID1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.370.0263
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-2.7220.244
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.3940.839
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9161.1040.0919
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 591.5120.488
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5810.818
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1040.851
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.5830.573
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.4890.678
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.6510.74
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.1580.678
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1450.539
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ID1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolID1
Nameinhibitor of DNA binding 1, dominant negative helix-loop-helix protein
Aliases dJ857M17.1.2; bHLHb24; DNA-binding protein inhibitor ID-1; ID; class B basic helix-loop-helix protein 24; dJ ......
Chromosomal Location20q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ID1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolID1
Nameinhibitor of DNA binding 1, dominant negative helix-loop-helix protein
Aliases dJ857M17.1.2; bHLHb24; DNA-binding protein inhibitor ID-1; ID; class B basic helix-loop-helix protein 24; dJ ......
Chromosomal Location20q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ID1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ID1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolID1
Nameinhibitor of DNA binding 1, dominant negative helix-loop-helix protein
Aliases dJ857M17.1.2; bHLHb24; DNA-binding protein inhibitor ID-1; ID; class B basic helix-loop-helix protein 24; dJ ......
Chromosomal Location20q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ID1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolID1
Nameinhibitor of DNA binding 1, dominant negative helix-loop-helix protein
Aliases dJ857M17.1.2; bHLHb24; DNA-binding protein inhibitor ID-1; ID; class B basic helix-loop-helix protein 24; dJ ......
Chromosomal Location20q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ID1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolID1
Nameinhibitor of DNA binding 1, dominant negative helix-loop-helix protein
Aliases dJ857M17.1.2; bHLHb24; DNA-binding protein inhibitor ID-1; ID; class B basic helix-loop-helix protein 24; dJ ......
Chromosomal Location20q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ID1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolID1
Nameinhibitor of DNA binding 1, dominant negative helix-loop-helix protein
Aliases dJ857M17.1.2; bHLHb24; DNA-binding protein inhibitor ID-1; ID; class B basic helix-loop-helix protein 24; dJ ......
Chromosomal Location20q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ID1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.